Select publications

Fulvestrant (ICI 182,780; Faslodex®)

Bundred N et al. ICI 182,780 (Faslodex), an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Proc ASCO 2001;Abstract 1660.

Cheung KL, Robertson JF. Fulvestrant. Expert Opin Investig Drugs 2002;11:303-308. Abstract

Cicatiello L et al. The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion. Mol Cell Endocrinol 2000;165:199-209.Abstract

Curran M, Wiseman L. Fulvestrant. Drugs 2001;61:807-13; discussion 814. Abstract

Elkak AE, Mokbel K. Pure antiestrogens and breast cancer. Curr Med Res Opin 2001;17:282-9. Abstract

England GM, Jordan VC. Pure antiestrogens as a new therapy for breast cancer. Oncol Res 1997;9:397-402. Abstract

Erikstein B et al. ICI 182,780 ('Faslodex') 250 mg monthly intramuscular (IM) injection shows consistent PK profile when given as either 1 x 5ml or 2 x 2.5 ml injections in postmenopausal women with advanced breast cancer (ABC). Proc ASCO 2001; Abstract 2025.

Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol 1997;15:840- 52. Abstract

Howell A. Faslodex (ICI 182780). An oestrogen receptor downregulator. Eur J Cancer 2000;36 Suppl 4:S87-8. Abstract

Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res 2001;7:4402s-4410s; discussion 4411s-4412s. Abstract

Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001;7:4369s- 4375s; discussion 4411s-4412s. Abstract

Howell A et al. Comparison of efficacy and tolerability of fulvestrant (Faslodex) with anastrozole (Arimidex) in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 2000;64(1):No abstract available.

Howell A et al. Pharmacokinetics, pharmacological and antitumour effects of the specific antioestrogen ICI 182,780 in women with advanced breast cancer. Br J Cancer 1996;74:300- 8. Abstract

Howell A et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995;345:29-30. Abstract

Hu XF et al. Circumvention of tamoxifen resistance by the pure antiestrogen ICI 182,780. Int J Cancer 1993;55:873-6. Abstract

Jones S. Fulvestrant ('Faslodex®') versus anastrozole ('Arimidex®') for the treatment of advanced breast cancer in postmenopausal women — safety update on the combined analysis of two multicenter trials. Breast Cancer Res Treat 2001;Abstract 455.

Long BJ et al. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol 1998;67:293-304. Abstract

Lu Q et al. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999;57:183-92. Abstract

Mauriac L. Fulvestrant ('Faslodex®') is effective in advanced breast cancer in postmenopausal patients with visceral metastases: Comparison with anastrozole. Breast Cancer Res Treat 2001;Abstract 452.

McClelland RA et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001;142:2776-88. Abstract

McClelland RA et al. Short-term effects of pure antioestrogen ICI 182,780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factoralpha protein expression in human breast cancer. Eur J Cancer 1996;32A:413-6. Abstract

Nawaz Z et al. The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. Cancer Res 1999;59:372-6. Abstract

O'Regan RM et al. Effects of the antiestrogens tamoxifen, toremifene and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 1998;90:1552-8. Abstract

Osborne CK. A double-blind randomized trial comparing the efficacy and tolerability of FaslodexTM (fulvestrant) with ArimidexTM (anastrozole) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 2000;64(1):Abstract 7.

Osborne CK et al. Selective estrogen receptor modulators: Structure, function and clinical use. J Clin Oncol 2000;18(17):3172-3186. Abstract

Parisot JP et al. The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor. Int J Cancer 1995;62:480-4. Abstract

Robertson JF. Estrogen receptor downregulators: New antihormonal therapy for advanced breast cancer. Clin Ther 2002;24 Suppl A:A17-30. Abstract

Robertson JF. Faslodex (ICI 182,780), a novel estrogen receptor downregulator, future possibilities in breast cancer. J Steroid Biochem Mol Biol 2001;79:209-12. Abstract

Robertson JF. ICI 182,780 (Fulvestrant)—the first oestrogen receptor down-regulator— current clinical data. Br J Cancer 2001;85 Suppl 2:11-4. Abstract

Robertson JF et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl] estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739- 46. Abstract

Robertson JFR. A comparison of the single-dose pharmacokinetics (PK) of 'Faslodex' (fulvestrant) 250 mg when given as either a one x 5-ml intramuscular (IM) injection or two x 2.5-ml injections in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 2000;Abstract 172.

Robertson JFR et al. Survival update from a phase II trial of fulvestrant ('Faslodex®') in tamoxifen-resistant breast cancer patients. Breast Cancer Res Treast 2001;Abstract 451.

Rosenberg Z and RS et al. Is ICI 182,780 an antiprogestin in addition to being an antiestrogen? Breast Cancer Res Treat 2000;60:1-8. Abstract

Smolnikar K et al. Treatment with the pure antiestrogen Faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Breast Cancer Res Treat 2000;63:249-59. Abstract

Vergote I. Evidence of continued sensitivity to endocrine agents in postmenopausal women with advanced breast cancer progressing on fulvestrant ('Faslodex®') treatment. Breast Cancer Res Treat 2001;Abstract 446.

Home · Search